Pegylated liposomal dexamethasone sodium phosphate - Enceladus Pharmaceuticals

Drug Profile

Pegylated liposomal dexamethasone sodium phosphate - Enceladus Pharmaceuticals

Alternative Names: Dexamethasone sodium phosphate - Enceladus Pharmaceuticals; Enc 0313; Liposomal dexamethasone - Enceladus Pharmaceuticals; Oncocort; PEG-liposomal dexamethasone sodium phosphate

Latest Information Update: 20 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enceladus Pharmaceuticals
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma; Prostate cancer

Most Recent Events

  • 12 Dec 2016 Chemical structure information added
  • 08 Nov 2016 Phase-I/II clinical trials in Prostate cancer (Metastatic disease, Monotherapy, Hormone refractory) in Netherlands (IV) (EudraCT2016-003121-42)
  • 12 Oct 2016 Phase-I/II clinical trials in Multiple myeloma (Second-line therapy or greater, Monotherapy) in Germany (IV) (EudraCT2014-005137-32)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top